Figure 6.

Adenosine participates in PP-induced depotentiation of SC LTP. A, When PLFS is delivered in the presence of 200 nm DPCPX, a competitive adenosine A₁ receptor antagonist, depotentiation is eliminated. B, Administration of 10 nm CCPA, an adenosine A₁ receptor agonist (solid bar), causes depotentiation of SC LTP (S1 pathway) and a form of LTD in a second independent SC input (S2). C, After induction of SC LTD by 10 nm CCPA, HFS of the SC input results in robust LTP. This LTP can be reversed by a second application of CCPA. Error bars indicate SEM. Traces in all panels show representative EPSPs obtained at the times specified with control responses shown as dashed lines. Calibration: 1 mV, 5 ms.